The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer

Osimertinib has been adopted as the standard therapy for T790M-mediated acquired resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC). The detection of EGFR T790M can be evaluated using different methods. The association between baseline T790M abundance and osimertinib efficacy has not been fully determined.A total of 144 advanced NSCLC patients...